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Well over a hundred years ago, Professor Julius Bredt embarked 
on a career pursuing and critiquing bridged bicyclic systems that 
contained ring strain induced by the presence of a bridgehead 
olefin. These endeavors founded what we now know as Bredt’s 
rule (Bredtsche regel). Physical, theoretical and synthetic organic 
chemists have intensely studied this premise, pushing the 
boundaries of such systems to arrive at a better-understood 
physical phenomenon. Mother nature has also seen fit to construct 
molecules containing bridgehead double bonds that encompass 
Bredt’s rule and for the first time this topic is reviewed in a 
natural product context. 
1. Introduction 
 Bredt’s rule (Bredtsche regel),[1] as derived by Professor 
Julius Bredt (Technische Hochschule Aachen, Figure 1 Bottom) 
in the early part of last century,[2] simply states that the terminus 
of a double bond cannot exist at the bridgehead position 
(branching positions) of a bridged bicyclic system {i.e. 
bicyclo[m.n.o] 1; Figure 1 top}. The premise of the rule is based 
solely on the overall strain imparted on the bridgehead double 
bond (p-orbitals) due to the distortion constraints imposed by the 
size of the bridging rings.[3] The term “anti-Bredt” system was 
later coined as examples that violated Bredt’s rule started to 
emerge,[4 ] that is, bridged bicyclic systems that contained, or 
were proposed to contain, a double bond at a bridgehead 
position.[5] 
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Figure 1. Top: Generalized structure of a bridged bicyclo[m.n.o] 
system showing a bridgehead double bond (anti-Bredt system); 
Bottom: Prof. Julius Bredt, Technische Hochschule Aachen.  
Fawcett proposed an empirical aspect to the rule to better 
predict violations of Bredt’s rule,[5a] which culminated in the S 
value. The S value is the sum of atoms contained in all bridges of 
the bridged bicyclic system, for example, a bicyclo[3.2.1]octane  
has an S value of 6. Thus, according to Fawcett’s 
generalization, bridged bicyclic systems with bridgehead double 
bonds with an S value ≥ 9 have the potential to be isolated, 
although a tentative upper limit value of 8 was conceivable. 
Systems with an S value of 7 could be observed but not isolated, 
whereas those with an S value 6 could be entertained as fleeting 
intermediates. Prelog,[ 6 ] concurrently proposed that only 
bicyclo[5.3.1] systems or larger (S ≥ 9) could contain a stable 
bridgehead double bond. Wiseman subsequently developed a 
more rigid hypothesis (excuse the pun) by comparing the stability 
of cis- and trans-cycloalkenes and translating that to bicyclic 
bridgehead double bond systems.[7 ,8] Wiseman concluded that 
when the larger of the two rings containing the double bond (i.e. 
m and o in 1; Figure 1 top) contained at least eight atoms (and in 
certain cases, seven), the bridged bicyclic system would be stable. 
The efforts of Fawcett, Prelog, and Wiseman were summarized 
by Köbrich as rules A, B and C in an attempt to better predict 
relative distortion energies.[5b]  
Rule A. For homologs with different S values, the ring strain 
varies inversely with S value.  
Rule B. For a given S value, the ring strain varies inversely with 
the size of the larger of the two rings with respect to which the 
bridgehead double bond is endocyclic.  
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Rule C. For a given bicyclic ring skeleton, the ring strain varies 
inversely with the size of the bridge containing the bridgehead 
double bond.[5b]  
 The predictive rules were ultimately refined by Schleyer 
using MMI empirical force field calculations,[9] which provided 
the “olefin strain (OS)” energy (which is directly related to the 
heat of hydrogenation), as the predictive tool. It should be noted, 
that Burkert and Ermer had calculated this phenomena earlier, 
[10][11] but in a limited capacity. Schleyer’s empirical rules, based 
on direct comparision of OS calculations to that of literature 
experimental data, facilitated classification of individual 
bridgehead olefins into three groups. 1) Isolable bridgehead 
olefins (OS ≤ 17 kcal/mol; e.g. bicyclo[3.3.3]undec-l-ene), 2) 
observable bridgehead olefins (17 kcal/mol ≤ OS ≤ 21 kcal/mol; 
e.g. bicyclo[4.2.l]non-l(9)-ene), and 3) unstable bridgehead 
olefins (OS ≥ 21 kcal/mol; e.g. bicyclo[2.2.2]oct-l -ene) (Figure 
2). Further clarification of these catergories were provided by 
Schleyer, being roughly defined as: 1) “Isolable” olefins are 
kinetically stable at room temperature; 2) “Observable” olefins 
are not isolable at room temperature but may be detected at lower 
temperatures spectroscopically; and  “Unstable” olefins are not 
spectroscopically observable at low temperatures, except perhaps 
in matrix isolation.[9] 
With these predictive rules established, chemists continued to 
pursue anti-Bredt systems; 1) to further interrogate the proposed 
rules, 2) to use as versatile synthetic intermediates,[12,13] but to a 
much lesser extent, 3) evaluate them in the context of natural 
product structure.[12,14 ] It was this latter point that overlapped 
with our fascination of constructing natural products that 
contained bridged bicyclic moieties {i.e. bicyclo[m.n.o]}.[ 15 ] 
Furthermore, and perhaps more importantly however, we had 
recently isolated a novel natural product that contained a 
bridgehead double bond, and therefore wanted to better 
understand the application of Bredt’s law to natural product 
systems.[16] In consideration of the above, and that it was Bredt’s 
century old work on the camphene and pinane natural product 
series that resulted in the formulation of the rule, it seemed fitting 
to review this special class of natural products for the first time.  
In order to provide a comprehensive survey of the field, the 
selection criteria for candidate inclusion within this article 
broadly include (with some exceptions) all natural products 
which contain a bridgehead olefin. Since Bredt’s rule was first 
conceived, it quickly evolved through the work of Fawcett, 
Prelog, Wiseman, and Köbrich, finally culminating in Schleyer’s 
system of bridgehead olefin stability (OS). Therefore, as 
understood within the context of this refined paradigm, Bredt’s 
rule is applicable to stable (isolable), unstable (observable 
fleeting intermediates), and non-existent (Schelyer unstable) 
bridged bicyclic systems. Although stable and isolable 
bridgehead olefinic systems can now be quantitatively 
rationalized with this refined model, nonetheless, the term ‘anti-
Bredt’ infers that a compound is unstable, and in the context of 
natural products, too unstable to be isolated. Therefore, by 
definition, it could be argued that most, if not all, isolated bridged 
bicyclic natural products containing a bridgehead olefin cannot 
be labeled anti-Bredt. That, is any natural product that appears in 
the literature must contain a degree of stability to exist in the 
natural environment, and to survive the manipulation process by 
the isolation chemist. Of course, Bredt himself was already aware 
towards the end of his career that examples containing larger 
rings would lead to violations of his rule.[4] On this premise many 
candidates are probably better viewed as containing bridgehead 
olefins rather than anti-Bredt systems. We have refrained at this 
point from presenting further views on whether the term anti-
Bredt should even be entertained in the context of natural 
products. This will be further explained in section 6, giving the 
reader the opportunity to digest the material presented, before 
considering the subsequent analysis.  
Lastly, the review does not include natural products 
containing the bicyclo[n.n.0] system (e.g. pteridanoside 2),[ 17 ] 
only select examples of the cyclophane type (e.g. longithorone B 
3)[18] as this has been recently reviewed,[19 ] and not the rigid 
fused ring type (e.g. TG-2 4) (Figure 2).[20] Furthermore, it is 
beyond the scope of this review to comprehensively cover 
synthetic studies towards this group of natural products. However, 
brief reference is made to conquered total syntheses, much of 
which has already been reviewed elsewhere, and synthetic 
studies where pertinent.  
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Figure 2. a) Examples that illustrate the 3 stability groups 
proposed by Schleyer. b) Examples of bridgehead olefin 
containing natural product systems not covered in this review i.e. 
bicyclo[n.n.0], cyclophane, and rigid fused ring type. 
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2. Structural reassignments based on 
Bredt’s rule 
Following his initial publications, Bredt spent a considerable 
amount of his time correcting articles publishing clear violations 
of his rule, mostly however, on products proposed from the 
chemical treatment of many terpenes.[5] To the best of our 
knowledge, only on one occasion were natural product structures 
contested by Bredt,[1b, 21 ] and that was the case of an early 
proposal by Bartelt for two anti-Bredt fenchene isomers (5 and 6) 
(Figure 3).[22] Today there are 6 known fenchene isomers, a-(7), 
b-(8), g-(9), d-(10), e-(11) and z-(12) (Figure 3), of which 5 and 6 
do not feature.   
5 6
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Figure 3. Top: Proposed anti-Bredt fenchene isomers by Bartelt 
and the 6 known fenchene isomers to-date (presented in the 
racemic form); Bottom: Wallach’s proposal for a-pinene (13) and 
corrected a-pinene (14) shown as a racemate. 
Wallach et al in 1907 suggested 13 as the chemical structure 
of α-pinene 14,[23] however, this was identified by Richter and 
Anschütz as incorrect based on the Bredt premise (Figure 4).[24] It 
was almost 70 years later, however, that a natural product 
skeleton was questioned due to the presence of a double bond 
placed at a bridgehead position. In 2008, Fraga and co-
workers,[ 25 ] argued convincingly that the chemical structure 
claimed by Chanudhuri et al as licamichauxiioic acid B (15),[26] 
which had considerable anti-cancer activity,[ 27 ] was incorrect. 
Although Fraga did not suggest a revised structure, the key to 
unmasking this error was the 1H and 13C NMR chemical shift 
comparison to licamichauxiioic acid A (16) (also proven to be 
incorrect) and known related systems (i.e. 17). For example, the 
reported carbon chemical shifts of 35.7 ppm for C-9 and 33.9 
ppm for C-11 were not consistent (i.e. significant downfield and 
upfield differences), and the 1H NMR chemical shifts for 15 and 
16 at positions H-9 and H-14 had disconcertingly similar values 
(i.e. 5.45 ppm and 5.44 ppm respectively) (Figure 4).[26]  
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Figure 4. Licamichauxiioic acids A (16) and B (15) including the 
parent structure 17. 
Williams and Savchenko recently identified neoveratrenone 
18,[ 28 ] isolated from the roots and rhizomes of Veratrum 
dahuricum (Turcz.) Loes. f.,[ 29 ] as a suspiciously anti-Bredt 
candidate. Re-analysis of the spectroscopic data present by Cong 
et al.[29] suggested, even in the absence of some 2D NMR spectra 
(e.g. COSY), that the proposed anti-Bredt structure was incorrect 
as initially indicated by missing expected correlations in the 
NOESY spectra. A further clue en route to the likely structure 
was the fact that Cong et al. also reported the isolation of 
verapatuline (19), which on additional literature searching 
revealed the structurally related synthetic compound, 20. 
Comparison of the 1H and 13C NMR very compellingly pointed 
to the reassigned structure 21 (Figure 5). 
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Figure 5. Neoveratrenone (18) and compounds 19 and 20 that led 
to the structural revision 21. 
Two further natural products, which fall into the same 
suspiciously anti-Bredt category have been reported. The first is 
hugonianene A 22,[ 30 ] isolated from the cytotoxic root bark 
extract of Hugonia busseana (a shrub found in the southern parts 
of Tanzania), which has received attention for its high activity 
against Anopheles gambiae mosquito larvae causing complete 
larval mortality. In the second case Paridhavi et al reported the 
isolation of rosacedrenoic acid 23 from the flowers of Rosa 
damascene an Indian flowering plant.[ 31 ] No 2D NMR was 
undertaken in the elucidation process of 23 (Figure 6). 
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Figure 6. Proposed chemical structures for isolates from Hugonia 
busseana and Rosa damascene, respectively. 
Williams et al utilised the ACDlabs NMR Structure 
Elucidator platform to aid in resolving the controversial 
proposals for hexacyclinol,[32] which agreed with the Rychnovsky 
proposal.[33] Although neither of the two structures qualifies for 
this review, in the course of formulating rules to limit impossible 
structure generation (as possible Structure Elucidator solutions to 
the analysis of inputted 2D NMR data), Bredt’s rule was applied 
to the algorithm. Having had many successful outcomes with 
ACDLabs Structure Elucidator ourselves, when solving complex 
natural product structures,[34] we would caution against outright 
exclusion of potential solutions using Bredt’s rule. Subsequent 
sections highlight the need for such caution. 
3. All carbon containing bicyclic bridgehead 
olefinic systems 
Note: for ease of bicyclic system classification within the all 
carbon, oxygen and nitrogen sections the smallest ring in each 
bridge has been selected.  
3.1 Bicyclo[4.3.1] systems 
The isolation of 24 by Munro and co-workers in 1988 
represents the first reported example of a naturally-occurring 
bicyclo[4.3.1]decene system bearing the bridgehead double 
bond.[ 35 ] The cytotoxic sesquiterpene 24 was isolated from a 
methanol/toluene extract of a New Zealand Eurypon sp. sponge 
through bioassay-guided separation, and the structure was 
established with standard NMR spectroscopic techniques. 
Cambie and co-workers subsequently isolated the related 
compound 25 from the same species in 1990 (Figure 7).[36] The 
relative instability of 25 alludes to the reactivity of the 
bridgehead double bond in this instance, which is in agreement 
with the stability rules proposed by Prelog for the 
bicyclo[4.3.1]decene system.[6] Note that Schleyer predicted the 
bicyclo[4.3.1] to be completely stable.  
OH
24
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25 O  
Figure 7. The New Zealand Eurypon sp. sponge isolates 24 and 
25 (flat and three dimensional view) reported by Munro and 
Cambie.  
In 2013, Tantillo and Nguyen published density functional 
theory (DFT) calculations probing the mechanism of formation 
of caryolene (30), a putative biosynthetic precursor to 24.[37] Of 
the two proposed mechanisms, a base-catalysed sequence (via 26 
to 29) with a tertiary carbocation minimum was predicted to have 
a relatively low barrier for the formation of 30 (Scheme 1). 
H + base
H base
base
H base
base
26 27 28
2930  
Scheme 1. The postulated mechanism of formation for caryolene 
(30) supported by DFT calculations. 
The groups of Iwagawa and Duh have reported the isolation 
of structurally-related anti-Bredt bicyclo[4.3.1]decene xenia 
diterpenoids from soft corals belonging to the genus Xenia. 
Compound 31 was isolated from Xenia florida,[ 38 ] whereas 
umbellacins C (32) and E (33) were isolated from Xenia 
umbellatta Lamarck (Figure 8).[39] Strong correlation of NMR 
spectroscopic data for compounds 31-33 with that of related 
natural products with a saturated bicyclo[4.3.1]decene skeleton 
aided in the processes of structure elucidation. The configuration 
of the ∆4,12 alkene in 31 was assigned as cis on this basis.[38] 
However, for 33, NOESY correlations from H-3 to H-12, and H-
4a to H-13 established the geometry of the ∆4,12 alkene as trans. 
Umbellacin E (33) (Figure 8) was found to exhibit cytotoxicity 
against murine P-388 lymphocytic leukemia with an ED50 value 
of 3.8 µg/mL.[39] 
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Figure 8. The umbellacins (31-33) isolated from the genus Xenia.  
In a screening campaign aimed at the discovery of inhibitors 
of squalene synthase and protein farnesyl transferase, Kaneko 
and co-workers identified the novel bicyclo[4.3.1]deca-1,6-diene 
natural products phomoidride A (34) and B (35) (Figure 9).[40] 
Compounds 34 and 35 were isolated from the fermentation broth 
of an unidentified fungus, collected from a juniper twig in Texas. 
The C-7 epimeric compounds, phomoidride C (36) and D (37), 
were subsequently isolated by Danishefsky and Sulikowski 
(Figure 9).[41][42 ] While the bridgehead alkene skeleton of the 
phomoidrides is stable at room temperature, Kaneko and co-
workers demonstrated that 34 is converted into 35 upon treatment 
with a catalytic amount of methanesulfonic acid, forming an 
internal acetal. Sulikowski and co-workers subsequently 
suggested that 35 is the biosynthetic precursor to the remaining 
three phomoidrides, where 36 and 37 are thermodynamic 
products.[42] Structure determination of the phomoidrides was 
achieved using NMR spectroscopy, and has since been confirmed 
through total synthesis of phomoidrides A (34) and B (35) 
[Nicolaou,[43a-c] Fukuyama,[43d] Shair,[43e] Danishefsky[43f]]. The 
biosynthesis, biological activity, total syntheses, and efforts 
towards the total synthesis of the phomoidrides have been 
reviewed previously by Wood et al.[ 43 g] In this article an 
overview was put forward regarding which systems can be 
absolutely defined as anti-Bredt. The conclusion was that the 
phomoidrides could not be classed as anti-Bredt, as Kaneko 
stated, because the bicyclo[4.3.1]decene system is predicted to be 
stable according to Wiseman’s assessment criteria (as well as 
Schleyer).  
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Figure 9. Phomoidrides A-D (34-37) (top and side view) originated 
from an unidentified Texan juniper twig fungus.  
3.2 Bicyclo[4.4.1] systems 
In 1983, Naya and co-workers presented the first example of 
a natural product containing a bicyclo[4.4.1]undec-1-ene 
skeleton.[44] Five novel sesterterpenoids, cerorubenic acid-I (38), 
cerorubenic acid-II (39), cerorubenic acid-III (40), cerorubenol-I 
(41), and cerorubenol-II (42) were isolated from the secretion of 
the scale insect Ceroplastes rubens Maskell (Figure 10). The 
structures of these compounds were determined by NMR 
spectroscopy. The bridgehead double bond of 38 was susceptible 
to slow oxidation in the air, reflecting the inherent strain of the 
system. In 1998 Paquette achieved the total synthesis of 
cerorubenic acid-III (40) in the form of its methyl ester.[45] 
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Figure 10. Cerorubenic acids and alcohols (38-42) from secretions 
of the scale insect.   
From the culture broth of a marine isolate of Penicillium 
citrinum, Crews and co-workers isolated two novel steroids, 
isocyclocitrinol A (43) and 22-acetylisocyclocitrinol A (44).[46] 
An initial comparison of the spectroscopic data of 43 with that of 
the previously known compound cyclocitrinol (45 – original 
structure) suggested that 43 was likely a new cyclocitrinol 
analogue.[47] However, upon extensive spectroscopic analysis, it 
was found that 43 and 44 did not resemble 45, and in fact 
contained an entirely novel four-ring system including a 
bridgehead double bond. The structural assignment for 44 was 
confirmed by an X-ray crystal structure, and as a result, the 
structure of 45 was revised to that of 46. [46,48] Compounds 43 and 
44 were found to have weak antibacterial activity against 
Staphylococcus epidermidis and Enterococcus durans (Figure 
11).[46]  
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Figure 11. Top: Isocyclocitrinol A (43) and 22-acetylisocyclocitrinol 
A (44) (flat and three dimensional view); Bottom: Original and 
revised structure of cyclocitrinol 46 isolated from Penicillium 
citrinum. 
In 2005, Rodrigues-Filho and co-workers reported the 
isolation of neocyclocitrinol, an epimeric mixture of novel 
bicyclo[4.4.1]undec-7,10-diene C25 steroids, akin to that 
reported by Crews, from the plant-derived fungus Penicillium 
janthinellum.[ 49 ] It was found that the isolated compounds 
showed strong spectroscopic similarities to 46, differing only in 
the C-17 side-chain, which aided in the structure elucidation of 
neocyclocitrinol. Unfortunately, the configuration of the ∆20,22 
alkene was not established, nor were the absolute configurations 
determined for C-23 and C-24 (Figure 11).  
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Figure 12. Additional cyclocitrinol family members isolated from 
Penicillium citrinum and janthinellum. 
Zhu and co-workers subsequently re-isolated the 
neocyclocitrinols, isocyclocitrinol A (43) and 22-
acetylisocyclocitrinol A (44), and a series of bicyclo[4.4.1]undec-
7,10-diene analogues (47-59) from cultures of the volcanic ash-
derived fungus Penicillium citrinum HGY1-5.[48] Extensive NMR 
analysis and X-ray crystallography allowed for the unambiguous 
assignment of structure and absolute configuration of these 
compounds. Comparison to the spectroscopic data reported by 
Rodrigues-Filho revealed that the reported epimeric mixture was 
composed of 47 and 49. The authors furthermore demonstrated 
that 43, 46, 53, and 58 are produced on exposure of 59 to acidic 
conditions, and that compounds 47-52, 54 and 55 are artifacts of 
the acid hydrolysis of 46 and 53 (Figure 12). 
Ergosterol (60), which was also found to be produced by both 
fungi,[49,48] is the proposed biosynthetic precursor to these 
unusual steroids. The proposed mechanism relies on the 
enzymatic activation of C-19 to generate an electrophilic center 
(61), which can react with the ∆5,6 alkene with concomitant 
oxidation of C-6 to produce cyclopropane intermediate 62.[49] 
Subsequent fragmentation of the electron-deficient cyclopropane 
generates the bicyclo[4.4.1]undec-7,10-diene skeleton of the 
cyclocitrinols (63) (Scheme 2). The C-17 side-chain of the 
cyclocitrinols could be accessed through oxidation of the 
ergosterol side-chain (64 to 65), followed by elimination of 
acetone to produce intermediate 66, which could undergo 
subsequent oxidations and rearrangements to produce the variety 
of observed functionality. Based on the proposed biosynthesis, 
the Zhu group undertook feeding studies of P. citrinum with [1,2-
13C2]-acetate and [2-13C]-acetate.[48] The resulting labeling 
patterns were consistent with Rodrigues-Filho’s hypothesis (see 
Scheme 2).  
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Scheme 2. Top: The proposed biosynthetic pathway to the 
cyclocitrinols (63) starting from ergosterol (60); Bottom: Postulated 
oxidative transformation of the C-17 side-chain of the cyclocitrinols 
(63). 
3.3 Bicyclo[5.3.1] systems 
The taxanes [e.g. taxol (67), Figure 13] are perhaps the best-
known class of natural products, which contain a bridgehead 
alkene, with in excess of 200 taxoids bearing this structural 
moiety isolated to date. The reader is referred to the existing 
reviews and articles, which discuss in depth the isolation, 
occurrence, synthesis, and biological activity of the 
taxanes.[50][51,52] 
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Figure 13. Taxol 67 (flat and three dimensional view), the best 
known taxane, used for the clinical treatment of various cancers.  
Isolated from an extract of Disynaphia halimifolia, 
disyhamifolide (68), was reported by Bohlmann and co-workers 
in 1981.[ 53 ] The authors proposed that 68 results from a 
transannular aldol reaction of the medium-sized ring 69, which 
could be derived from [3,3]-sigmatropic rearrangement and 
reduction of disnyaphiolide (70), which was also isolated from 
the same species (Scheme 3).  
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Scheme 3. Proposed transannular aldol reaction giving 
disyhamifolide (68). 
Appendino found that chloroform extracts of tanacetum 
vulgare var. crispum and T. vulgare chemotypes tested positive 
for the presence of peroxides.[54] From these extracts was isolated 
crispolide (71), a hydroperoxysesquiterpene lactone bearing a 
bridgehead double bond. The structure of crispolide 71 was 
initially solved utilising NMR spectroscopy, and was 
subsequently confirmed by X-ray crystallography of the diacetate 
of the natural product.[ 55 ] The authors proposed a possible 
biogenetic route to crispolide (71), invoking an early introduction 
of the peroxyl moiety, followed by an acid catalyzed transannular 
cyclisation of known natural product peroxyparthenolide (73) 
(Scheme 4).  
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Scheme 4. Crispolide (71) (flat and three dimensional view); 
postulated to arise from an acid catalyzed transannular cyclisation 
originating from 73. 
A related structure, 1β,5β-dihydroxyeriocephaloide (74) was 
subsequently isolated by Zdero and co-workers from the aerial 
parts of Eriocephalus kingesii Merxm. Et Eberle (Figure 14), 
which was proposed to be biogenetically produced by an 
equivalent mechanism (see Scheme 4).[56] 
HO
O O
HO 74  
Figure 14. 1β,5β-Dihydroxyericocephaloide (74) isolated from the 
aerial parts of Eriocephalus kingesii. 
3.4 Bicyclo[7.2.1] systems 
Shikoccidin (75) (Figure 15), determined by X-ray 
crystallography in 1979, was isolated as the minor diterpenoid 
from the aerial parts of Rabdosia shikokiana (Makino) Hara var. 
occidentalis (Murata) Hara by Eiichi Fujita et al.[ 57 ] Upon 
treatment of shikoccidin (75) with acetic anhydride under basic 
conditions, a 8,9-secokaurane was produced which was found to 
be identical to the mono-acetate of the major diterpenoid isolated 
from the plant. Comparison of spectroscopic data led to the 
assignment of this structure as the bridgehead alkene containing 
shikoccin (76). The structure of shikoccin 76 was later confirmed 
by X-ray analysis of the mono-acetate derivative.[58] Although  
76 was a potential Grob-type fragmentation product of 75[57] 
(Figure 15), they subsequently confirmed that 76 was most likely 
not an artifact of the isolation. This conclusion was drawn based 
on the fact that conversion to 76 was not observed upon 
treatment of 75 with oxalic acid in methanol.[60] Eiichi Fujita and 
co-workers have also described the isolation and structure 
elucidation of O-methylshikoccin (77), which succumbed to total 
synthesis in 1996 by Paquette et al. (Figure 15).[59,60] Paquette 
went on to write that, “Although Bredt’s rule is not at all violated 
in 77 [presumably as S ≥ 9], sufficient ring strain evidently 
resides in its bridgehead double bond to endow this site with 
heightened reactivity.”[60]  
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Figure 15. Shikoccidin (75), shown as a potential Grob-type 
fragmentation precursor of Shikoccin (76), and O-methylshikoccin 
(77) (flat and three dimensional view) isolated from Rabdosia 
shikokiana var. occidentalis.  
Since the 1979 publication of Eiichi Fujita et al., the 
structures of a variety of compounds related to shikoccin (76) 
have been determined. Though the isolation of shikodomedin 
(78) was described in 1979 (Figure 16),[ 61 ] the structure 
determination of the major diterpenoid component of Rabdosia 
shikokiana (Makino) Hara var. intermedia (Kudo) Hara was not 
reported until some years later. In 1982 Tetsuro Fujita and co-
workers documented the X-ray analysis of the structure arising 
from the mono-bromoacetate shikodomedin.[ 62 ] Shikodomedin 
(78) was found to have cytotoxic activity against the cultured rat 
mammary cancer FM 3A/B cell line.[62] The group also examined 
the diterpenoid chemistry of Rabdosia umbros var. latifolia, and 
isolated the new compound rabdolatifolin (79) (Figure 16), along 
with a number of known compounds.[63] 
OH
O
O
OH
H
H
OH
O
O
H
AcO
OAc
H
78 79  
Figure 16. Shikodomedin (78) isolated from Rabdosia shikokiana 
var. intermedia and rabdolatifolin (79) Rabdosia umbros var. 
latifolia. 
Takeda and co-workers isolated rabdoshikoccin A (80) and B 
(81) from Rabdosia shikokiana var. occidentalis (Murata) Hara 
(Figure 17).[64] Treatment of 81 with acetic anhydride in pyridine 
yielded the triacetate, which was found to be spectroscopically 
identical to peracetylated 78, confirming the assigned structure. 
The Takeda research group also reported the isolation of 
rabdoumbrosanin (82) from Rabdosia umbrosa (Maxim.) Hara 
(Figure 17).[65]  
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Figure 17. Rabdoshikoccin A (80) and B (81) isolated from 
Rabdosia shikokiana var. occidentalis and rabdoumbrosanin (82) 
from Rabdosia umbrosa.  
From the liverwort Lepidolaena taylorii, Perry and co-
workers re-isolated rabdoumbrosanin (82) along with 83-87 as 
minor components (Figure 18).[ 66 , 67 ] The compounds were 
assessed for cytotoxic activity against mouse P388 leukemia cells, 
and compounds 82 and 87 were found to be the most potent. 
Croton kongensis has also proven to be a source of these 8,9-
secokauranes, with the groups of Kittakoop and Li isolating new 
structures 88-90 from this plant (Figure 18).[68-70] Diterpenes 86 
and 88 were found to have both antimycobacterial and 
antimalarial activity.[68] 
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Figure 18. 8,9-Secokauranes extended family members 83-91.  
Kubo and co-workers presented an unusual member of this 
class of compounds with rabdohakusin (91) in which the 
bridgehead alkene is exocyclic to the five-membered ring (Figure 
18). The structure of rabdohakusin (91) was initially established 
with the aid of NMR spectroscopy. Oxidation of the allylic 
alcohol with manganese dioxide produced a conjugated enone 
whose NMR spectra differed significantly from that of previously 
reported 76, supporting the presence of the exocyclic alkene.[71] 
3.5 Bicyclo[7.3.1] systems 
Four families of structurally related natural products 
belonging to this category include the esperamicins (Figure 
19),[ 72 ] calicheamicins (Figure 20),[ 73 ] namenamicin,[ 74 ] and 
shishijimicins (Figure 21).[ 75 a] In addition to possessing a 
bridgehead double bond, all of these compounds (except 
esperamicin X (95)[72]) possess a enediyne unit, which constitutes 
six of the seven carbons in the bicyclo[7.3.1] system, and a 
highly unusual allylic trisulfide unit. The main structural 
difference between the families is found in the sugars that 
decorate the bicyclic core. The two former families were derived 
from microbial fermentation; the esperamicins were produced by 
cultures of Actinomadura verrucosospora, collected from Pto 
Esperanza, Argentina, and the calicheamicins were isolated from 
Micromonospora echinospora ssp. calichensis. Namenamicin 
and the shishijimicins were isolated from the tunicates 
Polysyncraton lithostrotum on Namenalala Island and Didemnum 
proliferum in southern Japan respectively.  
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Figure 19. The esperamicins A1, A2, A1b and X (92-95) isolated 
from Actinomadura verrucosospora, collected from Pto Esperanza, 
Argentina. The absolute configurations have not been determined, 
but are depicted as shown for the purpose of clarity and 
consistency. 
Standard spectroscopic and spectrometric analysis of various 
chemical degradation products, in addition to the intact natural 
products, allowed for the structure determination of the 
esperamicins and the calicheamicins. The formation of 
dihydrothiophene 97 through reduction of pseudoaglycon 96 with 
excess triphenylphosphine was key to establishing the structure 
of the bicyclic core (Scheme 5).[73] Likewise, the discovery of 
esperamicin X (95) greatly aided the structure determination 
efforts of the esperamicins,[72] and also added further evidence 
for the proposed biological mechanism of action (more below). 
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Scheme 5. Triphenylphosphine mediated reduction of aglycon 96 
to give dihydrothiophene 97 (top and side views by 90° rotation) 
was instrumental in the elucidation of the calicheamicins’ core.  
The reactive bridgehead alkene of these natural products, in 
concert with the allylic trisulfide and enediyne unit, is key to 
their antitumour antibiotic properties (Scheme 6). Reduction of 
the allylic trisulfide 98 causes the corresponding sulfide (99) to 
undergo a 1,4-addition onto the bridgehead enamide. This allows 
the ends of the enedyne (100) (which were kept apart previously 
by the bridgehead double bond) to approach and undergo 
reductive aromatization (Bergman cyclisation) via a 1,4-diyl 
species (101).[75b] This biradical species is capable of hydrogen 
abstraction from the DNA backbone, leading to strand scission. 
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Scheme 6. Postulated chemical process that facilitates the mode 
of action of the enediyne-type anti-tumor antibiotics. Reduction of 
trisulfide 98 leads to conjugate addition of the resultant sulfide (99) 
to the bridgehead enamide, which allows a Bergman-type 
cyclisation on enediyne 100 to take place, leading to the formation 
of the active 1,4-diyl species 101. 
R1O
X
OMe
OMe
S
O
O
OH
O
N
H
O
HO
R2O
O
102 R = NHCO2Me, X = Br, R1 = Y, R2 = A, R3 = iPr
103 R = NHCO2Me, X = Br, R1 = Y, R2 = A, R3 = Et
104 R = NHCO2Me, X = I, R1 = H, R2 = A, R3 = Et
105 R = NHCO2Me, X = I, R1 = Y, R2 = H
106 R = NHCO2Me, X = I, R1 = Y, R2 = A, R3 = iPr
107 R = NHCO2Me, X = I, R1 = Y, R2 = A, R3 = Et
108 R = NHCO2Me, X = I, R1 = Y, R2 = A, R3 = Me
O
OH
HO
MeO
OHN
MeOR
3
Y = A =
O
NH
OHMeS3
O
OMe
 
Figure 20. Calicheamicins β1Br, γ1Br, α2I, α3I, β1I, γ1I, δ1I (102-108) 
isolated from Micromonospora echinospora ssp. Calichensis. 
Of the four families encompassing the esperamicins (Figure 
19), calicheamicins (Figure 20), namenamicin and shishijimicins 
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(Figure 21), only calicheamicin γ1I (107) has succumb to total 
synthesis [Nicolaou 1992;[76] Danishefsky 1995[76f]]. 
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Figure 21. Namenamicin 109 and shishijimicins A-C (110-112) 
isolated from Polysyncraton lithostrotum on Namenalala Island and 
Didemnum proliferum form southern Japan respectively. 
3.6 Bicyclo[9.2.1] systems 
The only representative within this class is the diterpene 
erythrolide K (115) (Scheme 7), isolated from a sample of the 
Caribbean gorgonian octocoral Erythropodium caribaeorum 
collected in Tobago, as disclosed by Mootoo in 1997.[77] Note 
that both bridgehead positions contain a double bond. The 
compound was characterized by NMR spectroscopy, with the 
unusual structure further secured by X-ray crystal structure 
analysis. 
 Based on the isolation of structurally related family 
members [e.g. erythrolide A (113)], it was postulated that 
erythrolide K (115) is biosynthetically derived from 113 via a 
[1,5]-sigmatropic hydrogen shift of the H-10 to C-3 with 
concomitant rupture of the cyclopropane unit (across the C-1 – 
C-14 bond). This transformation has been achieved in a synthetic 
setting (Scheme 7). 
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Scheme 7. Erythrolide K (115) isolated from Erythropodium 
caribaeorum, and its postulated biosynthesis from erythrolide A 
(113). 
3.7 Bicyclo[9.3.1] systems 
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Figure 22. The phomactin and Sch bicyclo[9.3.1]pentadec-1-ene 
series, comprising of Sch 47918 (116) (flat and three dimensional 
view), Sch 49026 (117), Sch 49027 (118) and phomactins B (119), 
B1 (120), B2 (121), C (122), E (123), F (124), I (125; 13-epi, 126) 
and J (127). 
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The phomactins (Figure 22),[78][79] isolated from the marine 
fungus Phoma sp., were found to be platelet activating factor 
antagonists, which are of potential benefit for the treatment of 
inflammatory disease states and ischemic disorders.[80] Not too 
surprisingly, the pharmaceutical companies Sankyo (Japan) and 
Schering-Plough (USA) showed considerable interests in these 
natural products, as did synthetic chemists.[81,82] The Goldring,[83] 
Hsung,[84] and Wulff[85] groups are amongst those who have been 
successful in the total synthesis of these compounds. The 
structures of Sch 47918 (116),[78c] E (123),[78e] I (125),[78g] and J 
(127)[78g] were all solved by X-ray crystallography (Figure 22). 
 Sch 49027 (118),[78c] is unique amongst this collection in 
that the double bond at the bridgehead could theoretically 
tautomerize to give the corresponding ketone. However, the 
oxygen bearing carbon of the enol had a chemical shift of 148.1 
ppm, clearly indicating an olefinic carbon despite any perceived 
strain (Figure 22). The sp2 hybridization at this bridgehead 
position, rather than inducing strain, is clearly energetically 
favourable for this system. 
Duh, who contributed to the bicyclo[4.3.1]decene class in 
section 3.1 above, discovered the cespitularin family of 
diterpenes (Figure 23), isolated from the Formosan soft coral 
Cespitularia hypotentaculata.[ 86 , 87 ] The structures were 
determined solely by NMR spectroscopy. Many of these 
compounds exhibited cytotoxicity against the cancer cell lines 
A549 (human lung adenocarcinoma), HT-29 (human colon 
adenocarcinoma) and P-388 (mouse lymphocytic leukemia).[88] 
However, cespitularin C (128) was particularly potent, exhibiting 
ED50 values of 0.12, 8.86 and 0.01 µg/mL against the 
aforementioned cell lines respectively. 
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Figure 23. Cespitularins C (128), D (129) and E (130) isolated 
from the Formosan soft coral Cespitularia hypotentaculata. 
Shen uncovered two further cespitularin-type natural 
products, cespihypotins C (131) and D (132), from Cespitularia 
hypotentaculata Roxas (Xeniidae) in Taiwan in 2006 (Figure 
24).[89,90] Their structures were deduced by NMR spectroscopic 
methods. HMBC correlations between the gem-dimethyl protons 
and the bridgehead sp2 carbon were important in identifying the 
bridgehead olefin of cespihypotins C (131) and D (132). 
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Figure 24. Cespihypotins C (131) and D (132) isolated from 
Cespitularia hypotentaculata Roxas (Xeniidae). The putative 
structure verticillene (133) is believed to be the biogenetic 
precursor of the cespitularins and cespihypotins, supported by 
133b. 
Like the phomactins, the cespitularin-type structures have 
shared lineage with taxane natural products. Indeed, Shen and 
coworkers postulated that the cespitularins and cespihypotins all 
arise from verticillene (133) (Figure 24),[89,90] a putative structure 
that is proposed to be the biogenetic precursor of the taxane 
natural products. The recently reported compound 1 (133b), from 
Trichoderma atroviridae (UB-LMA), an endophytic fungus 
isolated from Taxus baccata trees, further supports this 
biosynthetic hypothesis (Figure 24).[90b] 
3.8 Bicyclo[10.2.1] systems 
The solitary entry in this section was discovered only very 
recently by Reddell, Parsons and Williams from the stems of 
Croton insularis (Baill) in a campaign aimed at discovering new 
anti-cancer agents from the Australian rainforest, in collaboration 
with EcoBiotics Ltd.[16] The bicyclo[10.2.1]pentadec-2,6,13-
triene ring system of EBC-219 (136) was determined by NMR 
spectroscopy, specifically through the observation of key HMBC 
correlations. DFT calculations determined that four low-energy 
conformations could be adopted by the macrocyclic ring system. 
These featured either in-plane or perpendicular alignments of the 
alkene groups, with the perpendicular conformers giving 3D 
structures that are the most consistent with the NOESY NMR 
spectral data (Scheme 8, top). Calculations were also utilized to 
determine the absolute configuration of EBC-219 (136) by 
comparison of experimental and calculated CD spectra and found 
to be 1S, 5R, 8S, 9R (Scheme 8, middle).  
The structurally related 1,2-dicarbonyl bearing EBC181 
(134), which was also isolated from the same species, was 
proposed to be the biogenetic precursor of EBC-219 (136). It can 
be envisaged that the bridgehead double bond could arise from a 
5-exo-trig cyclization of a γ-enol (of type 135) of EBC181 (134) 
onto its C-5 ketone (Scheme 8, bottom). 
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Scheme 8. EBC-219 (136) isolated from Croton insularis (Baill). 
Top: Low-energy conformation with key NOEs. Bottom: Postulated 
biosynthetic conversion from EBC181 (134) via 135, and key 
HMBC correlations assigning the bridgehead alkene shown on 
EBC-219 (136). 
3.9. Bicyclo[13.3.1] systems 
The longithorones,[18, 91 ] and longithorols,[ 92 ] are exquisite 
natural products, owing to their curious polycyclic structure, the 
possibility of multiple atropisomers, and, significant to this 
review, multiple bridgehead alkenes [see also erythrolide K (115) 
(Scheme 7)] (Figure 25).[ 93 ] For instance, the archetypal 
compound in this family, longithorone A (137), possesses in the 
same molecule two bridgehead olefins within bicyclo[7.3.1] and 
[12.2.2] systems, and a greater bicyclo[13.3.1] system that 
contains three bridgehead alkenes. That is, five of the seven 
bridgehead positions contain a double bond! 
The longithorones are farnesylated quinones isolated from 
the tunicate Aplidium longithorax. The structures of 
longithorones A (137) (the most complex member of the 
family),[91] B (3, Figure 2), and E (138) were all secured by X-ray 
crystallography,[18] while the others were determined through 
NMR spectroscopy. Longithorols A (141) and B (143) were 
unstable, presumably as the hydroquinone moieties were easily 
oxidized to the corresponding quinones; hence, the structures of 
the corresponding peracetylated derivatives 142 and 144 were 
elucidated instead. 
Schmitz proposed that the key step in the biogenesis of these 
compounds was a [4+2] cycloaddition of farnesyl-quinone units 
147 and 148 giving rise to the bicyclo[13.3.1] system.[91] In 
Shair's enantioselective total synthesis of (-)-longithorone A 
(137),[ 94 ] this [4+2] cycloaddition was successfully modeled 
using appropriately protected synthetic equivalents of 147 and 
148 to furnish the bicyclic core, giving credence to the proposed 
biosynthetic pathway (Scheme 9). 
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Figure 25. The longithorones A (137), E (138), F (139), G (140), H 
(145), I (146), and longithorols A (141; pentaacetate, 142)[95] and B 
(143; pentaacetate, 144) isolated from the tunicate Aplidium 
longithorax. 
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Scheme 9. The proposed key step in the biosynthesis of 
longithorone A (137) involving a [4+2] cycloaddition of quinone 
units 147 and 148 to furnish the polycyclic core. 
4. Oxygen containing bicyclic bridgehead 
olefinic systems 
4.1. 10-Oxabicyclo[4.3.1] systems 
The oxygenated series are dominated by mono-oxygenated 
bicyclic ring systems and a good starting example is FR182877 
(149) (Figure 26). In 1996 the Fujisawa Pharmaceutical 
Company patented a novel antimitotic agent isolated from a 
strain of Streptomyces sp. No.9885,[96] characterized by 2D NMR 
techniques and X-ray crystallography of a derivative as (+)-
FR182877 (149) (Figure 26).[ 97 ] Synthetic chemists,[ 98 ] most 
notably Sorensen[99] and Evans,[100] were immediately attracted to 
this molecule, not only to the elegant structural architecture, but 
also to the striking anti-tumor activity. For example, FR182877 
(149) displayed potent activity against both murine ascitic tumor 
P388 and Colon 38 solid tumors prolonging the life span of the 
tumor xenograph bearing mice, in addition, to other common cell 
lines.[97]  
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Figure 26. (–)-FR182877 (149) isolated from a strain of 
Streptomyces sp. No.9885. The work of Sorensen determined that 
the originally proposed (+)-enantiopode was incorrectly 
assigned.[97d,99] 
The pinnacle attraction to this audience, however, was the 
fact that FR182877 (149) was found to be quite unstable due to 
the reactivity of the bridgehead double bond. It was found to 
react with molecular oxygen to form an epoxide,[97c] and with 
various nucleophiles in a Michael addition fashion.[99] These 
observations are unsurprising because the bridgehead double 
bond contained within FR182877 (149), whether considered as a 
10-oxabicyclo[4.3.1]decene or a 2,7-dioxabicyclo[4.3.1]decene 
system, has Fawcett S = 8 and Wiseman trans-8 atom status, 
meaning it lies on the boundary of being classed as an anti-Bredt 
system. 
4.2. 11-Oxabicyclo[4.4.1] systems 
In 1991 Jereisterol A (150) (Figure 27) was isolated by 
Minale and co-workers from the pacific sponge Jereicopsis 
graphidiophora Lévi & Lévi in the north of New Caledonia at a 
depth of 225 m.[101] The structure of this rare 3-methoxy-8,9-
secosteroid was deduced by comparing 13C NMR data to that of 
known seco-steroids and those partially synthesized by the 
authors. Subsequent to the original discovery of this structural 
motif a number of reports later emerged in this area. The first 
from a second group in Napoli led by Costantino and co-workers 
who isolated compounds 4 (152) and 5 (151) from the Senegalese 
sponge Microscleroderma spirophora (Figure 27).[102] Tylopiol 
A (153) (solved by X-ray crystallography), and tylopiol B (154), 
reported by Wu et al.[103] were the only compounds of this class 
to be isolated from a terrestrial source. The source, namely 
Tylopilus plumbeoviolaceus (Snell. et Dick.) Sing., is an edible 
bitter fungus [family Strobilomycetaceae (Boletales)] widely 
distributed in the central area of Yunnan Province, China (Figure 
27). 
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Figure 27. Jereisterol A (150), compounds 4 (152) and 5 (151), 
and tylopiol A (153) (flat and three dimensional view) and B (154). 
A number of related structures bearing polysaccharide 
residues have also been isolated. Ebel and co-workers evaluated a 
sample of Erylus lendenfeldi (Geodiidae) collected off the Jordan 
coast in the gulf of Aqaba (Red Sea), discovering the steroidal 
saponin eryloside L (155) (Figure 28).[104] The same group later 
reported sarasinoside M (156) (Figure 28), isolated from the 
Indonesian sponge Melophlus sarassinorum. [ 105 ][ 106 ] Some 6 
years later sarasinoside M (156) was isolated again, by a group 
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led by Oh and Shin, from the tropical sponge Lipastrotethya sp. 
collected from Chuuk, Micronesia, along with sarasinoside Q 
(157) (Figure 28).[107] Oh and Shin,[107] also demonstrated that 
sarasinoside M (156) and Q (157) display cytotoxicity against 
A549 and K562 cell lines, in addition to weak inhibitory activity 
against Na+ /K+ -ATPase.  
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Figure 28. Eryloside L (155), and Sarasinosides M (156) and Q 
(157) isolated from Erylus lendenfeldi, Melophlus sarassinorum 
and Lipastrotethya sp., respectively. 
4.3. 11-Oxabicyclo[5.3.1] systems 
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Figure 29. Briareolate esters A-C (158-160) and H (161) isolated 
from Briareum asbestinum. Flat and three dimensional view for 
158 shown at bottom.  
Extracts of Gorgonian octocorals (Briareum asbestinum), 
collected off the coast of Tobago, were investigated in a 
collaborative effort between the groups of Mootoo, McLean and 
Tinto. Using a combination of 2D NMR spectroscopy and X-ray 
crystal structure analysis, the structure of methyl briareolate 
(158) was elucidated (Figure 29).[108 ] A subsequent full paper 
disclosed two further family members (159-160),[109] and a later 
re-isolation paper reported 161.[ 110 ] They were later renamed 
briareolate esters A (158), B (159), C (160) and H (161) (Figure 
29).[110] No biological studies were reported. 
4.4. 8-Oxabicyclo[5.4.1] systems 
Francisco et al. disclosed that cystoseirol A (162) (Figure 30) 
was obtained from a brown alga (Cystoseira mediterranea) 
occurring along the Mediterranean coastline. It could also be 
isolated from C. stricta and C. tamariscifolia.[111] A subsidiary 
publication by this group announced cystoseirols B (163), C 
(164), D (165) and E (166) (Figure 30), also found in various 
sources of Cystoseiraceae, i.e. C. mediterranea (Banyuls sur 
Mer), C. tamariscifolia (Atlantic coasts), and C. stricta (Nice), 
around France.[112] The Francisco papers specifically commented 
that they had identified a natural product that “contains a bridge-
head, anti-Bredt, double bond” “(in a large enough system to be 
accommodated)”, but interestingly no citation to Bredt was 
provided. 
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Figure 30. Cystoseirols A-E (162-166) isolated from Cystoseira 
mediterranea, C. stricta and C. tamariscifolia. 
4.5. 11-Oxabicyclo[6.2.1] systems 
de Vivar et al investigated the sesquiterpenoid constituents of 
members of the Compositae family isolating a new 
germacranolide, zexbrevin (167), from the aereal part of the 
schrub Zexmenia breujfolia (Figure 31).[ 113 ] Hydrogenation 
(Pd/C/H2) of zexbrevin (167) afforded tetrahydrozexbrevin (168) 
(Figure 31), which surprisingly left the bridgehead double bond 
untouched. Some 15 years later a correction to the source of 
isolation was reported, where it was discovered that the actual 
natural source of zexbrevin (167) was Viguiera greggi (subgenus 
Calanticaria).[ 114 ] X-ray crystallographic confirmation of the 
elucidated structure was also reported, but well after the original 
elucidation.[115] Budlein-A (169), was also isolated by de Vivar 
from Viguieru buddleiaeformis (Figure 31).[ 116 ] Its epimer, 
lychnophorolide A (170), as confirmed by X-ray crystallography, 
was isolated from Lychnophora affinis by Le Quesne and 
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Raffauf,[ 117 ] as was lychnophorolide B (171) (Figure 31). 
Lychnophorolide A (170) showed significant cytotoxicity 
activity; a factor of ten greater than that of related eremantholide 
A (172) (Figure 31).[117,118] Total syntheses of eremantholide A 
(172) have been completed, notably by Hale,[119] Boeckman,[120] 
and Tadano.[121] Given that 171 was close in structure to that of 
atripliciolide tiglate (173), reported by Bohlmann (Figure 31),[122] 
and that of many other family members in this series,[123] led Le 
Quesne and Raffauf to suggest that a close relationship must exist 
between the genera Eremanthus, Lychnophora, Piptolepis, and 
Vanillosmopsis in the family Vemoniae.[117]  
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Figure 31. 11-Oxabicyclo[6.2.1] sesquiterpenoids (167-173) 
isolated form the genera Eremanthus, Lychnophora, Piptolepis, 
and Vanillosmopsis in the family Vemoniae. Zexbrevin (167); flat 
and three dimensional view.  
4.6. 9-Oxabicyclo[6.2.2] systems 
Two natural product groups fall into this ring size class, 
namely, the macquarimicins [A (174) and B (175)] and the 
cochleamycins [A (176) and A2 (177)] (Figure 32), which are 
closely related to FR182877 (149) discussed in section 4.1 {10-
Oxabicyclo[4.3.1], Figure 26}. In 1984 Jackson et al., working 
for Abbott Laboratories, reported the macquarimicins [A (174) 
solved by NMR and B (175) by X-ray crystallography] as low 
potency anti-anaerobic microbial metabolites from two soil 
fermentation broths (Micromonospora chalcea).[124] Around the 
same time, the cochleamycins [A (176) and A2 (177)] were 
reported by Shindo and Kawai from the Kirin Brewery 
Company,[ 125 126127 ] having been isolated from a Japanese soil 
Streptomyces sp. (DTI36), and found to show antitumor 
antibiotic activity. Biosynthesis studies were undertaken using 
13C and 2H labeled precursors, which assisted in proposing a 
plausible biosynthetic route involving an intramolecular Diels-
Alder (IMDA) reaction.[ 128 ] It was this IMDA biosynthetic 
proposal that lured synthetic chemists to approach the synthesis 
of these captivating targets. Total syntheses were reported from 
the groups of Tadano [2004, Macquarimicins A and B (174-
176)],[129] Tatsuta [2003, (+)-Cochleamycin A (176)],[130] Roush 
[2004, (+)-Cochleamycin A (176)],[ 131 ] and Lee [2009, (-)-
Cochleamycin A (176) formal].[132]  
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Figure 32. Macquarimicins [A (174) and B (176)] and the 
cochleamycins [A (176) and A2 (177)] isolated from soil bacteria. 
4.7. 11-Oxabicyclo[8.2.1] systems 
Jatrophones, are well known for their prevalent cancer 
biology,[123]  and thus will not be extensively reviewed herein. 
Jatrophone (178) (Figure 33), was isolated from extracts of 
Jatropha gossypiifolia L. (Euphorbiaceae), in a search for tumor 
inhibitors by Kupchan and Bryan.[133] The structure of 178 was 
elucidated by X-ray crystallography. Notable total syntheses 
include Smith [1981, racemic Jatrophone],[134] Stille and Hegedus 
[1990, racemic Jatrophone],[ 135 ] and Wiemer [1992, (+)-
Jatrophone][136]. 
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Figure 33. Jatrophone (178) isolated from Jatropha gossypiifolia L. 
Other members of this class include the abyssomicins (Figure 
34), which have attracted substantial attention from isolation and 
synthetic chemists alike. The initial isolation of abyssomicins B-
D (179, 184, 180) was disclosed through a collaborative effort 
led by Fiedler and Süssmuth in 2004.[137] The attraction, beyond 
the structural beauty, to this suite of natural products was the 
potent antibiotic activity (inhibition of the pABA biosynthetic 
pathway),[137] which in combination with the isolation from the 
“deep” [Japanese Sea, depth 289m, Verrucosispora sp. (AB-18-
032)] gave inspiration for the name. In 2007 a subsequent 
collaborative report investigating the same species, spanning 
knowledge learned through synthesis, unveiled abyssomicins G 
(187) and H (186), and atrop-abyssomicin C (185).[ 138 ] 
Interestingly, within this time frame, it was discovered that this 
chemotype from the deep was not restricted to the marine 
environment. The first terrestrial isolations originated from 
Senegal and Mexico in the form of abyssomicin E (Sattler et 
al,[139] 181) and abyssomicin I (Igarashi et al,[140] 188), which 
were isolated from soil Streptomyces sp. This was followed by 
the isolation of ent-homoabyssomicin B (189) from a German 
soil sample, as reported by Laatsch and co-workers.[141] More 
recently, groups lead by Liu, Capon, and Zhang, driven by an 
anti-tuberculosis screening program, reported abyssomicins J 
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(190), K (182), and L (183), isolated from a sediment-derived 
actinomycete, Verrucosispora sp in the South China Sea (depth 
2733m).[142] Total syntheses of this class have been prevalent, 
with syntheses completed by Sorensen [2005,[143] abyssomicin C 
(184)], Nicolaou [2006,[144 ] abyssomicin C (184) and atrop-C 
(185); 2007,[145] abyssomicin D (180)], and Bihelovic and Saicic 
[2012,[146] atrop-abyssomicin C (185)]. 
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Figure 34. The abyssomicin antibiotics (179-190).  
4.8. 12-Oxabicyclo[9.2.1] systems 
The oxabicyclo[9.2.1] series are dominated by the pterolides 
[furancembranolides, e.g. kallolide A (191a)], which maintain a 
reasonable portion of diterpene families isolated from gorgonian, 
and other related corals {see also 4.3. 11-oxabicyclo[5.3.1] 
systems}. This area has been extensively reviewed,[147] and thus 
the two structures presented here (Figure 35) are given with the 
sole purpose of presenting a class exemplar. Many of the 
furancembranolides, can be considered heterocyclophanes (see 
cyclophane review[19]),[148] which are outside the scope of this 
review, but are believed to be direct oxidative precursors to the 
furan opened members e.g. Kallolide C (191b). Kallolide C 
(191b) (Figure 35) was isolated in the Bahamas from 
Pseudopterogorgia kallos, a marine octocoral within the 
abundant genus of sea whips.[149]  
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Figure 35. Kallolide A (191a) and Kallolide C (191b) isolated from 
Pseudopterogorgia kallos, and polymaxenolide (192) discovered in 
the hybrid soft coral species, Sinularia maxima · Sinularia 
polydactyla. 
4.9. 14-Oxabicyclo[11.2.1] systems 
Polymaxenolide (192), elucidated by X-ray crystallography, 
was isolated from a hybrid soft coral (Sinularia maxima · 
Sinularia polydactyla) (Figure 35). This natural product (192) is 
interesting from an evolutionary perspective. Not only is 192 
obtained from a hybrid marine species, but the organism utilizes 
a hybrid biosynthetic pathway, producing a hybrid structure 
comprising cembrane-type diterpene and africanane-type 
sesquiterpene frameworks.[150] 
4.10. 4,23-Dioxabicyclo[18.2.1] systems 
The last representative in the oxygenated series is tuscolid A 
(193) (Figure 36), isolated from culture extracts of 
myxobacterium (Sorangium cellulosum, strains So ce1401 and 
So ce1383) as reported by Höfle. NMR spectroscopy was used to 
deduced the flat structure assisted by biosynthetic 13C-labelled 
feeding studies.[151] 
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Figure 36. Tuscolid A (193) isolated from Sorangium cellulosum. 
5. Nitrogen containing bicyclic bridgehead 
olefinic systems 
Only a small number of alkaloids containing a bridgehead 
olefin were identified. These include the haliclamines A-F (200-
205), halicyclamines A-B (206-208), saraines 1-3 (194-196) and 
isosaraines 1-3 (197-199), which, unsurprisingly, are all 
biogenically linked.[152] 
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Figure 37. Saraines 1-3 (194-196) and Isosaraines 1-3 (197-199) 
isolated from Reniera sarai. 
The saraines 1-3 (194-196) (Figure 37) ,[153] which bear a 3-
azabicyclo[10.3.1]hexadec-1-ene core, were isolated from the 
Mediterranean sponge Reniera sarai, (order Haplosclerida) 
collected in the bay of Naples, Italy. Reduction of the carbonyl to 
the corresponding alcohols facilitated structure determination by 
subsequent conversion to Mosher esters, in conjunction with 
extensive 2D NMR spectroscopy. Approximately three years 
later diastereomers of the saraines, namely the isosaraines 1-2 
(197-198), were isolated from the same marine sponge,[154] with 
saraine 3 and isosaraine 3 (199) discovered over a decade 
later.[153c] 
Around the time the isosaraines (197-199) (Figure 37) were 
discovered, haliclamines A and B (200-201) (Figure 38) were 
isolated from a sponge of the genus Haliclona collected off the 
Japanese Island of Hiburi-jima in the Uwa Sea.[ 155 ] Both 
haliclamine A and B inhibited sea urchin (Hemicentrotus 
pulcherrimus) fertilized egg cell division, and more importantly 
inhibited the growth of leukemia cell lines L1210 (IC50 0.9 
ug/mL) and P388 (0.39 ug/mL).[155] More recently, haliclamines 
C (202), D (203), E (204) and F (205) were isolated by Köck et 
al. from the Arctic sponge Haliclona viscosa.[ 156 , 157 ] The 
haliclamides are possibly the most intriguing examples in this 
class in that there are two bridgehead double bond systems 
contained within the same molecule, and furthermore, the 
nitrogen atom makes up one of the bridge junctions in each 
system (Figure 38). Of the haliclamines only A has succumb to 
total synthesis [1997, Morimoto].[158]   
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Figure 38. Haliclamines A-F (200–205) isolated from Haliclona 
viscosa.  
The last in this series are the halicyclamines A (206), B (207) 
and 22-hydroxyhalicyclamine A (208). Crews and co-workers 
reported the isolation of halicyclamine A (206) from Haliclona 
sp.; a massive, soft textured, olive green colored, tubular sponge, 
collected from Biak, Indonesia.[159] It showed good inhibition of 
inosine monophosphate dehydrogenase (IMPDH) (1 µg/mL), 
which is a potential cancer chemotherapy target. Much more 
recently, however, halicyclamine A (206) was found to be a lead 
anti-tuberculosis agent,[ 160 ] and an anti-dormant mycobacterial 
substance with the mechanism of action correlating to the DedA 
protein.[161] 22-Hydroxyhalicyclamine A (208) was later reported 
by Fusetani,[162] isolated from the marine sponge Amphimedon sp. 
To complete the set, halicyclamine B (207), elucidated by X-ray 
crystallography, was later reported by Crews and Clardy, isolated 
from the marine sponge Xestospongia sp. obtained from Sangihe 
Islands, Indonesia.[163 ] Structurally, halicyclamines A (206), B 
(207) and the hydroxyl derivative (208) are the only examples 
which contain two nitrogen atoms within the bicyclic core, giving 
rise to a 3,16-diazabicyclo[14.3.1]icos-1-ene system in the case 
of A (206) and hydroxy (208), and 3,9-
diazabicyclo[12.3.1]heptdec-1-ene system in the case of B (207) 
(Figure 39). 
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Figure 39. Halicyclamines A [206), B 207 flat and three 
dimensional view)] and 22-hydroxyhalicyclamine A (208). 
6. Anti-Bredt or Bridgehead olefin? 
Although it is somewhat ironic that Bredt’s rule was 
developed through the study of simple terpenoid natural products, 
its application in this context remains uncertain. Should (or can) 
the term ‘anti-Bredt’ be applied to natural products containing a 
bridgehead olefin? In addition to the philosophical argument that 
a natural product is inherently stable for the purposes of isolation, 
the crux of the problem is that Bredt’s rule (including the 
refinements of the last century) is based on investigations of 
fundamental and functionally unadorned parent bicyclic ring 
systems, unlike the plethora of functionalities and substitutions 
that are commonplace in natural products. The stability of 
bridgehead olefins can vary substantially depending on the 
presence or placement of these functional groups and additional 
architectural features.[9c] 
These reasons compel us to propose that the anti-Bredt 
terminology is not directly applicable to natural products. Instead 
we feel that it is more instructive to evaluate the strain of 
naturally occurring bridgehead olefins quantitatively rather than 
qualitatively. Far from the natural product community 
abandoning Bredt’s rule, it is this approach that strikes at the 
heart of the bridgehead olefin strain phenomenon first discovered 
by Bredt.   
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To this end, Schleyer’s model of olefin strain (OS) energy is 
well poised to act as an important indicator, via computed OS 
values, of bridgehead olefin instability, rather than to attempt a 
classification as anti-Bredt or not. However, OS calculations of a 
suitable range of bridgehead olefins would lead to a prohibitively 
sizeable in silico study considering the number of natural 
products identified in this review.  
Therefore, we herein suggest, and illustrate, two alternative 
methods based on in vitro data that allow the bridgehead olefin 
strain of natural products to be measured, or perhaps more 
importantly, better appreciated 
Analysis 1:   As elegantly described by Shea,[12a] in analogy 
to a trans-cycloalkene a bridgehead olefin is subject to torsional 
distortion. This distortion creates a twisting effect, bending the π 
bond out of co-planarity, sequentially diminishing p orbital 
overlap with decreasing ring size. Subsequently, the sp2 centers 
rehybridize by incorporating s character into the p orbitals of the 
π bond, resulting in pyramidalization of both sp2 centers. The 
degree of distortion and pyramidalization can be quantified by 
the angles t and c respectively (Figure 40). Although X-Ray 
crystallographic data cannot be used to determine t, nor c, 
directly, these angles can be determined by measuring either of 
the torsional angles YC1C2W (F1) or ZC1C2X (F2) (Figure 40). 
Due to the rehybridization, and ensuing pyramidalization 
however, F1 and F2 are now non-equivalent, and therefore, the 
torsional distortion t is defined as an average [i.e. t = (f1 + f2)/2].  
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Figure 40. The projected view along a torsionally distorted double 
bond; distortional parameters c and t. Adapted from reference 
[12a]. 
Utilizing this mode of analysis, specifically concentrating on the 
degree of distortion (t), select X-ray crystal structures of the all- 
carbon containing series (i.e. 44, 71, 76 and 116; Figure 41) were 
examined, covering the bicyclo[4.4.1], [5.3.1], [7.2.1] and [9.3.1] 
systems.  
O
HO
H
H
H
OHOAc
H
H
22-Acetylisocyclocitrinol A (44)
O
HO
HO OAc
Crispolide (71)
HO
O O
HOO
HOO OH
O
H
O
Bicyclo[4.4.1] system
Bicyclo[5.3.1] system
OH
O
O
H
AcO
H
OAcO H
OH
O
Bicyclo[7.2.1] system
Shikoccin (76)
O
H
O
CHO
Sch 47918 (116)
O
O
O
H O
O
OH
Bicyclo[9.3.1] system
 
Figure 41. All carbon candidates 44, 71, 76 and 116, solved by X-
ray crystal structure analysis, used to evaluate bridgehead bond 
lengths and torsional values. Crispolide 71 solved as the diacetate, 
and Shikoccin 76 solved as the mono acetate.  
Unfortunately, no examples of smaller ring systems have 
been solved by X-ray crystal structure analysis. However, in this 
instance, X-ray crystal structures of advanced synthetic 
intermediates towards the phomoidrides {bicyclo[4.3.1] system} 
were available from the work of Nicolaou,[43a] Wood[164] and 
Clive[165] et al. Thus, compounds 209 and 210 (Figure 42) were 
evaluated together with the above chosen natural products (i.e. 44, 
71, 76 and 116) (Figure 41 and Table 1). 
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Figure 42. Shea’s bridgehead olefin (210) and Nicolaou’s 
intermediate (209). 
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Table 1. Bridgehead bond lengths and torsional (t) values for 
compounds 44, 67, 71, 76, 116, 209 and 210.  
Entry 
[Ref] 
Bridgehead 
Olefin 
length (Å)[a] 
Bridgehead 
Olefin 
distortion 
(t)[a][b][c] 
Bicyclo[m.n.o] 
system 
209[43a] 
210[12a,
166] 
1.312 
– 
8.2° 
6.8° 
[4.3.1] 
71[55] 
67[167] 
1.328 
1.351 
3.4° 
3.6° 
[5.3.1] 
44[46] 1.331 2.6° [4.4.1] 
76[58] 1.334 2.6° [7.2.1] 
116[78c] 1.326 0.4° [9.3.1] 
[a] See cited literature for standard deviations. [b] The value of t 
was extracted from reported X-ray crystallographic data using the 
program Mercury.[168] [c] Variation in determining t values can exist 
due to the accuracy of the calculated hydrogen positions, or the 
level of refinement obtained in the process of solving the X-ray 
crystal structure. For example, a structure measured at low 
temperature might be expected to have a lower refinement value 
providing a greater degree of hydrogen atom certainty or 
probability. 
A clear trend is evident from the t values listed in table 1 
above, in that, on increasing ring size {i.e. [4.3.1] to [9.3.1]} the 
degree of bridgehead olefin twisting decreases. The most strained 
system is the phomoidride intermediate 209 within the 
bicyclo[4.3.1] series. The distortion angle of 8.2° is quite high 
compared to the value of 6.8° in 210, which is more 
representative of an archetypal bicycle[4.3.1] system. This is 
most likely due to other skeletal strain features present in 209,[9c] 
but nevertheless compares well with the parent system 
210.[12a,166] The vales of 3.4° and 3.6° for crispolide (71) and 
taxol (67), respectively, compare well for the [5.3.1] series, with 
decreasing values through to 0.4° for the [9.3.1] system [i.e. Sch 
47918 (116)].   
In the case of the oxygen containing bicyclic bridgehead 
olefinic systems, t values were determined for tylopiol A (153), 
methyl briareolate (158) and tetrahydrozebrevin (168) (Figure 43, 
Table 2).  
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Figure 43. Oxygen bridged candidates (i.e. 153, 158 and 168) 
solved by X-ray crystal structure analysis, used to evaluate 
bridgehead bond lengths and torsional values.  
Table 2. Bridgehead bond lengths and torsional (t) values for 
compounds 153, 158, and 168.  
Entry 
[Ref] 
Bridgehead 
Olefin 
length (Å)[a] 
Bridgehead 
Olefin 
distortion 
(t)[a][b][c] 
Bicyclo[m.n.o] 
system 
158[108] 1.348 0.5° [5.3.1] 
153[103] 1.218 
1.389 
7.6° 
4.3° 
[4.4.1] 
168[115] 1.355 8.7° [6.2.1] 
[a] See cited literature for standard deviations. [b] The value of t 
was extracted from reported X-ray crystallographic data using the 
program Mercury.[168] [c] Variation in determining t values can exist 
due to the accuracy of the calculated hydrogen positions, or the 
level of refinement obtained in the process of solving the X-ray 
crystal structure. For example, a structure measured at low 
temperature might be expected to have a lower refinement value 
providing a greater degree of hydrogen atom certainty or 
probability. 
The oxygen-bridged series are more difficult to analyze as the 
suggested trend is opposite to the all carbon series, in that, larger 
rings systems contain more strained bridgehead olefins. On 
closer inspection of these natural product candidates, however, it 
is apparent that skeletal structure is most likely a substantial 
contributor to the observed bridgehead olefin twisting. For 
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example, tylopiol A (153) (t = 7.6° and 4.3°) contains two 
bridgehead olefins with significant differences between the two 
bridgehead bond lengths (D = 0.171Å). Meanwhile, with methyl 
briareolate (158) (t = 0.5°) the bridgehead olefin is conjugated to 
a second alkene, which can potentially provide stability to the out 
of plane p orbital on the bridgehead olefin exo carbon through 
adjacent p orbital overlap. In the case of tetrahydrozebrevin (168) 
the torsional distortion value (t = 8.7°) is unexpectedly high, 
matching more closely the value of the all-carbon bicyclo[4.3.1] 
systems. Contrary to this argument, however, is that the 
bridgehead olefin is conjugated to a carbonyl, and it has resisted 
hydrogenation. A similar observation is made in the nitrogen-
bridged example, halicyclamine B (207). It might be expected 
that for such a large ring system {i.e. bicyclo[12.3.1]/[10.3.1] 
system} a very low or even negative t value be found, but instead 
t is relatively large (i.e. 3.7°) most likely due to the olefin 
residing in the smallest bridge (Figure 44). 
N
N
H
Halicyclamine B (207)
H
H N
HN
H
1.307Å
τ = 3.7
 
Figure 44. Halicyclamine B (207) bridgehead bond lengths and 
torsional values obtained from the reported X-ray crystal structure 
analysis. 
Analysis 2: Another assessment criteria useful in the context 
of anti-Bredt natural product evaluation, is the chemical 
reactivity of the bridgehead olefin (which has been highlighted 
throughout, but not fully considered). In both the bicyclo[4.4.1] 
and the oxobicyclo[4.3.1] systems, cerorubenic acid-I (38)[44] and 
FR182877 (149)[97c] were observed to undergo slow aerial 
oxidation to give sp3 bridgeheads in epoxides 211 and 212 
(Scheme 10).[169] Sesquiterpene 25 was also reported to be 
unstable and the two co-isolates (213 and 214) were deemed to 
be artifacts of isolation arising from reaction at the bridgehead 
double bond. These observations suggest that 25, 38 and 149 are 
members of Schleyer’s “observable fleeting intermediates” class 
(i.e. unstable), but perhaps towards the more stable (long-lived) 
end of the spectrum. Indeed, although we urge discouragement of 
the ‘anti-Bredt’ terminology in relation to natural products, the 
observably unstable bridgehead olefins are very close to being 
naturally occurring violations of the classical Bredt’s rule. By 
extension, natural products that have certain bridgehead 
functionality (e.g. epoxide or alcohol, i.e. 213, Scheme 10) could 
potentially be extrapolated from a naturally occurring classical 
anti-Bredt reactive intermediate. 
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Scheme 10. Cerorubenic acid-I (38) and FR182877 (149) aerial 
oxidation to epoxides 211 and 212, respectively. Sesquiterpene 25 
artifacts of isolation 213 and 214.  
7. Summary and Outlook 
It is of no wonder that the stability and classification of 
natural products containing bridgehead olefins was unclear. In 
the course of preparing this review we noticed that a significant 
proportion of canvassed articles did not refer to Bredt’s rule, 
which strongly suggests anti-Bredt classification uncertainty. We 
hope this review brought clarification and indeed, introduced a 
helpful framework of evaluating bridgehead olefin containing 
natural products. 
Lastly, we feel that Julius Bredt himself probably would 
never have imagined his legacy would continue into modernity, 
especially as he was already aware that violations of the rule 
were on the horizon. Nevertheless, the occurrence in nature of 
architecturally beautiful and biologically active candidates, 
unearthed by the isolation chemist, suggest that the field will 
continue to develop attracting the attention of biologists and 
chemists alike. 
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